醫療新知 > Cellink以3D列印製造腫瘤以對抗癌症 / Cellink Turns to 3D Printing Tumors to Combat Cancer

Cellink以3D列印製造腫瘤以對抗癌症 / Cellink Turns to 3D Printing Tumors to Combat Cancer











瑞典生物科技公司Cellink設計出生物墨水(biological ink),可被各種不同3D列印機用於製造不同種類的細胞組織,目前正研究以3D列印製造腫瘤以對抗癌症。此將能看到實際上腫瘤如何生長,以及如何對不同治療做出反應。



Cellink的最新活動已引發3D列印界內外的極大興趣。該公司日前宣布,已與法國公司CTI Biotech簽署合作協議,製造可用於藥品檢測的腫瘤。透過將生物墨水與病患癌細胞混合的方式,在不危害人體健康下進行對腫瘤的深入研究。















該公司創辦人Erik Gatenholm與Hector Martinez Avila也創造售價最低僅10,000美元的組織3D列印機,引發大量的需求。




Cellink Turns to 3D Printing Tumors to Combat Cancer

by | Jan 9, 2018 | 3D Printing, Medical 3D Printing, Science & Technology |

It may seem counterintuitive, but the Swedish biotech company Cellink is actually fabricating tumors in an effort to combat cancer. The company, which exploded on the scene in 2016, has risen to fame as a result of their biological ink, designed to be used by a variety of 3D printers to create different types of cell tissues. The founders, Erik Gatenholm and Hector Martinez Avila, then went on to create a tissue printing 3D printer that sells for only $10k and the demand has been phenomenal.
The market for bioprinting is expected to triple between 2016 and 2021, to around $1,33 bn.
[Image courtesy of Cellink]

The company has been in the news so often, it’s nearly exhausting trying to keep up, but their latest activity is one that has garnered great interest both in and outside of the 3D printing community. The company announced on Monday that they have signed a partnership with CTI Biotech, a French company based in Lyon, to fabricate tumors that can be used for pharmaceuticals testing. The ability to mix their own inks with cells from patients’ cancers will allow them to produce tumors that can be subjected to intense research without endangering human lives. As Gatenholm explained in an interview with Business Insider Nordic:



“You will be able to see how a tumor grows and how it would respond to different treatments. It’s a very relevant and a realistic model for research.”



Cellink sells both the 3D printers and the bio-ink. The printers are priced between $10,000 and $39,000. [Image courtesy of Cellink]




Currently, Cellink produces bioprinted noses and ears for cosmetics and medical research, as well as creating cubes comprised of cells that can allow researchers to experiment with human organ cells. Branching out into the production of tumors is less of a leap and more of an expansion, and the implications are profound. Developing new medicines to combat cancer is both a high priority for the public and something that can only necessarily proceed slowly as the cancer itself lives inside of a person, who cannot simply be subject to any and all ideas about what might combat the disease. This means that a slow, cautious approach can strangle some innovative ideas or simply create interminable roadblocks to the advancement of others.


The ability to use bioink to create tumors frees researchers of the many ethical concerns associated with testing as well as reduces the costs associated with such research activities. Currently, a great deal of the medical testing being undertaken to advance cancer treatments occurs on animals, something that Cellink hopes will be able to be replaced with these made-in-the-lab tumors. The driving idea is that not only will new methods of addressing cancerous tumors be able to be developed, but that also medical researchers can begin to explore personalized means of delivering cancer treatments, hopefully with fewer negative side effects.




Cellink’s founders Hector Martinez Avila (left) and Erik Gatenholm (right), with Cellink CCO Ariel Kramer at Nasdaq First North for the IPO. [Image courtesy of Business Insider Nordic]




This effort is part of Cellink’s mission to be a global leader in bioprinting and to change the face of medicine as we know it. In addition, they hope to one day be able to print human organs, although, Gatenholm admits, that possibility is still most likely 15 to 20 years in the future. Interest in their ideas has been strong and confidence in their company continues to grow, as demonstrated by the fact that only 10 months after the company was founded, there was a 1000% oversubscription to their IPO. During their first year, they have already reached profitability, something not common for tech startups.


What do you think of this news? Let us know your thoughts; join the discussion of this and other 3D printing topics at 3DPrintBoard.com or share your thoughts below.




文章來自: 物聯網 – 智慧城市 / 3Dprint.com

中: https://www.digitimes.com.tw/iot/article.asp?cat=158&id=0000522680_X9U7ROVH7DAP4D1R7EOV4

ENG : https://3dprint.com/199654/cellink-3d-printing-tumors/



(重磅新聞) ASCO2021值得關注的臨床腫瘤學科研成果
ASCO2021值得關注的臨床腫瘤學科研成果 [醫藥新聞] 美國臨床腫瘤學會(ASCO)代表所有關心癌症患者的 […]
港大醫學院發現肝癌細胞耐藥性及腫瘤復發的新分子機制 2021年06月01日 港大醫學院發現肝癌細胞耐藥性及腫瘤 […]
中大研究發現半數受訪兒童癌症康復者曾使用替代補充療法 或存在「藥療相互作用」風險
中大研究發現半數受訪兒童癌症康復者曾使用替代補充療法 或存在「藥療相互作用」風險 2021年6月1日 負責是次 […]
中大醫學院兩學者榮膺「2019年全球20位頂尖轉化研究科學家」 榜上唯一亞洲學府 盧煜明教授連續第四年獲選 2020年10月29日
中大醫學院兩學者榮膺「2019年全球20位頂尖轉化研究科學家」 榜上唯一亞洲學府 盧煜明教授連續第四年獲選 2 […]
港大醫學院發現Vδ2-T細胞外泌體 可作為治療EB病毒相關腫瘤的新方法
港大醫學院發現Vδ2-T細胞外泌體 可作為治療EB病毒相關腫瘤的新方法 2020年10月08日 港大醫學院發現 […]
主題:肺癌免疫治療 嘉賓:吳偉麟(癌症資訊網創辦人)、潘智文醫生(臨床腫瘤科專科醫生)   相關文章 […]
雄激素阻斷療法(androgen deprivation therapy,ADT)或保護前列腺癌患者免受COVID-19感染
雄激素阻斷療法(androgen deprivation therapy,ADT)或保護前列腺癌患者免受COV […]